Intended for healthcare professionals


NICE recommendations on tirzepatide for weight loss could increase NHS access

BMJ 2024; 385 doi: (Published 05 June 2024) Cite this as: BMJ 2024;385:q1239
  1. Emma Wilkinson
  1. Sheffield

The National Institute for Health and Care Excellence (NICE) has recommended another weight loss drug for adults with a body mass index (BMI) of at least 35 (or lower in some ethnic minority groups) and at least one weight related comorbidity, under draft guidance now out for consultation.1

Weekly injections of tirzepatide (Mounjaro, Eli Lilly) should be offered alongside diet and exercise support, the committee ruled after reviewing clinical trial evidence showing that a 15 mg dose was associated with a 20% reduction in weight when compared with placebo.

Data from the Surmount-1 study found that after 72 weeks 96.3% of participants taking tirzepatide had lost 5% or more body weight, which compared with 27.9% in the placebo group, who also received diet and exercise advice.

Eli Lilly had submitted a proposal to make tirzepatide available …

View Full Text

Log in

Log in through your institution


* For online subscription